3种方案治疗2型糖尿病的成本-效果分析

Analysis of cost-effectiveness of 3 therapeutic schemes for type 2 diabetes mellitus

目的比较3种方案治疗2型糖尿病的临床疗效并进行药物经济学成本-效果分析。方法采用回顾性调查方法,150例糖尿病患者随机分为二甲双胍组(A)、阿卡波糖组(B)、米格列奈组(C),疗程均为12周。观察3组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2h PBG)、糖化血红蛋白值(Hb A1c),运用成本-效果分析方法进行评价。结果治疗12周后,3组患者的FBG、2h PBG、Hb A1c均不同程度降低。3种治疗糖尿病方案的成本分别为208.32、529.20和609.84元;总有效率分别为70.00%、74.00%和82.00%;成本-效果比分别为2.98、7.15和7.44;B、C组相对于A组的增量成本-效果比分别为80.22元和33.46元。结论 C组米格列奈钙片具有较好的药物经济学优势。

Objective To compare the curative effects and pharmacoeconomic costs of 3 therapeutic schemes in the treatment of type 2 diabetes mellitus. Methods By a retrospective survey method, 150 cases of type 2 diabetes mellitus patients were randomly divided into 3 groups. The 50 patients in group A were given Metformin hydrochloride sustained-release tablets, the 50 patients in group B were given Acarbose tablets, and the 50 patients in group C were given Mitiglinide calcium tablets for 12 weeks. The levels of fasting blood glucose （FBG）, 2-h postprandial blood glucose （PBG） and HbA1c were observed in the 3 groups before and after treatment. The cost-effectiveness was evaluated by pharmacoeconomic method. Results After 12 weeks, the FPG, 2-h PBG and HbAlc of the 3 groups were decreased to some extent. The costs of the 3 therapeutic schemes were 208.32, 529.20 and 609.84 yuan, respectively. The total effective rate of the groups A, B and C were 70.00%, 74.00% and 82.00%, respectively. The cost-effectiveness ratio of the groups A, B and C was 2.98, 7.15 and 7.44 respectively. Using the group A as a reference, ？C/？E for the groups B and C were 80.22 and 33.46 yuan respectively. Conclusions Among the 3 therapeutic schemes, Mitiglinide for the group C has pharmacoeconomic advantage in treating type 2 diabetes mellitus.